Half-Life Extended Monoclonal Antibody

Mechanism

Related News

Spyre Therapeutics details ECCO presentations and SPY003 Phase 1 follow-up

Apr 17, 2026

Spyre Therapeutics announced ECCO 2026 presentations featuring 20-week follow-up from the Phase 1 SPY003 study and details of the SKYLINE-UC platform study. The company is also seeking to raise $403 million in a follow-on stock offering.

Invivyd advances Phase 3 VYD2311 program and measles antibody candidate

Apr 12, 2026

Invivyd reported progress in the Phase 3 DECLARATION trial of VYD2311, with top-line data now expected in Q3 2026 after a sample size increase of about 500 subjects. The company also aligned with the FDA on the LIBERTY Phase 3 study, a pediatric study plan for DRUMMER, and advanced measles antibody candidate VMS063.